Accelerate Diagnostics Profit Margin

The latest profit margin for AXDX is -427.82% as of December 2024. That compares with -465.56% in the prior-year period — up 8.1% year over year. That is below the Healthcare sector average of 13.71%. Investors often review this figure alongside Accelerate Diagnostics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AXDX's profit margin moved from -465.56% to -427.82% — a 8.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Accelerate Diagnostics's valuation or profitability profile.

Against Healthcare companies, AXDX currently prints -427.82% for profit margin, while the sector average sits near 13.71%. That is roughly 3220.3% below the sector mean. Large gaps often invite a closer look at Accelerate Diagnostics's growth, margins, and balance sheet.

Profit Margin shows how effectively Accelerate Diagnostics converts resources into returns. At -427.82%, AXDX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -465.56% in the prior-year period — up 8.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AXDX's profit margin (-427.82%), review year-over-year change from -465.56%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.